Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 13/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17516260 | 0.83 | ALDH1A1 (0.48) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL16644927 | 0.79 | ALDH1A1 (0.34) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL14276878 | 0.76 | NAMPT (0.45) | GAAALDH1A1KMT2A | |
| SCHEMBL12443455 | 0.76 | PDE4A (0.47) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL16316832 | 0.76 | OXTR (0.38) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL611402 | 0.75 | OXTR (0.42) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL17518846 | 0.74 | ALDH1A1 (0.38) | OXTRAVPR1AAVPR2AVPR1BGAA | |
| SCHEMBL16644930 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL16059596 | 0.72 | NPC1 (0.59) | OXTRAVPR1AGAARAB9AALDH1A1 | |
| SCHEMBL20343561 | 0.72 | ALOX5 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2978425-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046581-A1 | Factor XIa Inhibitors | F11, F12, TFPI | OXTR 2174/4885AVPR1A 4263/4885AVPR2 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.